SBF-CM
Folder Details

Folder ID: 120220
Reg No: (b)(7)(E)

Author: (b)(6); (b)(7)(C)
Addressed To: ODEQ

Location: ODEQ
Due: 03/22/2012
Received: 3/12/2012
Date Sent: 3/22/2012
Response:

Security: A-AES
Abstract: (b)(4) 2012 procurement quota increase for hydromorphone
Signature: B. Boockholdt

Doc Categories: (b)(6); (b)(7)(C)
Doc Types: ODG

Action: Recommendation and Comments
Requested Activity:
Response Notes:

5/12/2015 12:00:31 PM
Memorandum

Subject: 2012 Procurement Quota Increase Request
Hydrocodone (DFN: 630-08.2)

Date: MAR 12 2012

To: Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From: Christine A. Santorius, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:
As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant’s customers. The application enclosed contains sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant’s enclosed customer list. Specifically, ODQ requests information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant’s quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject: 2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date: MAR 16 2012

To: Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section (ODQ)
Office of Diversion Control

From: Barbara J. Bockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On March 12, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant’s customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-two (92) of (b)(4) customers as well as an in-depth investigation of (b)(4).

The below listed information was found on (b)(4) customers:

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)
Based upon a review of customers, ODG recommends that ODQ limit the quota granted to this company. has five (5) customers that are Under Review/Investigation and one (1) that is retired.

We are available to discuss quantitative levels at your convenience. If you have any questions pertaining to this information, please feel free to contact me or SC.
Folder Details

Folder ID: 120391
Author: (b)(6); (b)(7)(C)
ODEQ

Reg No: (b)(7)(E)

Addressed To: ODEQ
Location: ODEQ
Due: 03/30/2012
Received: 3/20/2012
Date Sent: 3/22/2012
Response:

Security: A-AES
Abstract: Unit Dose 2012 procurement quota increase for oxycodone memo
Signature: B. Boockholdt

Doc Categories: A-AES
Doc Types: (b)(6); (b)(7)(C)
ODG 03/29/2012 3/21/2012

Action: Recommendation and Comments
Requested Activity:
Response Notes:
Memorandum

Subject: Unit Dose (b)(4); (b)(7)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

To: Barbara Boockholdt,
Chief
Regulatory Section
Office of Diversion Control

From: Christine A. Sarberud, Ph.D.
Chief
UN Reporting & Quota Section
Office of Diversion Control

Date: MAR 2 0 2012

Background:
As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject: Unit Dose 2012 Procurement Quota Increase Request
Oxycodone (DFN:630-08.2)

Date: MAR 21 2012

To:
Christine A. Sannerud, Ph.D, Chief
UN Reporting and Quota Section
Office of Diversion Control

From:
Barbara J. Bockholdt, Chief
Regulatory Section
Office of Diversion Control

On March 20, 2012, this section received your memorandum requesting a review of Unit Dose’s customers list, specifically, information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Unit Dose provided a list of customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Unit Dose for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me or SC.
Folder Details

Folder ID: 120920
Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)
ODEQ

Addressed To:

Location: ODEQ
Due: 04/27/2012
Received: 4/17/2012
Date Sent: 4/23/2012
Response: 

Security: A.AES
Abstract: (b)(4)
2012 procurement quota increase request for oxycodone

Signature: C. Sannerud
Doc Categories: 
Doc Types: (b)(6);(b)(7)(C)

Action: Recommendation and Comments
Requested Activity: 
Response Notes: 04/24/2012 4/23/2012
Memorandum

Subject
(b)(4)
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

To
Barbara Hoockholdt
Chief
Regulatory Section
Office of Diversion Control

From
Christine A. Sannertud, Ph.D.
Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

Date
APR 17 2012

2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Background:
As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject
2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)

Date APR 20 2012

To
Christine A. Sannerud, Ph.D., Chief Drug & Chemical Evaluation Section (ODQ) Office of Diversion Control

From
Barbara J. Bockholdt, Chief Regulatory Section (ODG) Office of Diversion Control

On April 17, 2012, this section received your memorandum requesting a review of a quota increase submitted by ODQ is requesting a review of customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred and twenty-five (125) of customers as well as an in-depth investigation of

The below listed information was found on customers:

Currently Under Review/Investigation

Currently Under Review/Investigation

Currently Under Review/Investigation

Currently Under Review/Investigation

Currently Under Suspension

Vol. II Page 447
Based upon a review of [redacted] customers, ODG recommends that ODQ adjust the quota granted to this company. One of [redacted] customer is currently under [redacted]; fourteen (14) customers are under Review/Investigation, and three (3) are retired.

Quota to [redacted] should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me [redacted] or SC [redacted]
SBF-CM

Folder Details

Folder ID: 120811
Author: (b)(6); (b)(7)(C)
Addressed To: Barbara Boockholdt
Location: ODEQ
Due: 04/22/2012
Received: 4/12/2012
Date Sent: 4/25/2012
Response:

Abstract: (b)(4) 2012 procurement quota increase request for hydrocodone
Signature: Christine Sannerud

Doc Categories: (b)(6); (b)(7)(C)
Doc Types: ODG

Action: Recommendation and Comments
Requested Activity:
Response Notes:

4/27/2015 2:12:06 PM
Memorandum

Subject: 2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date: APR 12 2012

From: Christine A. Sannerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

To: Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

Background:
As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant’s customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant’s enclosed customer list. Specifically, ODQ requests information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant’s quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject
2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date
APR 2 3 2012

To
Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From
Barbara J. Boeckholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On April 12, 2012, this section received your memorandum requesting a review of a quota increase submitted by [b](4). ODQ is requesting a review of [b](4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-nine (99) of [b](4) customers as well as on [b](4).

The following information was found on [b](4) and the below listed customers:

Order to Show Cause Requested

(b)(4);(b)(6);(b)(7)(C);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

(b)(4);(b)(7)(E)
Because four of customers are currently under review/investigation and ODG recommends that ODQ adjust the quota allotted accordingly.

If you have any questions pertaining to this information, please feel free to contact me or SC.
SBF-CM
Folder Details

Folder ID: 120810
Reg No: [DK7/E]

Author: [b](6);[b](7)(C)
ODEQ

Addressed To:,

Location: ODEQ
Due: 04/22/2012
Received: 4/12/2012
Date Sent: 4/19/2012

Security: A-AES
Abstract: [b](4) 2012 procurement quota increase request for oxycodone
Signature: Barbara Boockholdt

Doc Categories:
Doc Types:

[b](6);[b](7)(C) ODG 04/19/2012 4/18/2012

Action: Recommendation and Comments
Requested Activity:
Response Notes:

4/28/2015 9:47:35 AM
Memorandum

Subject: 2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date: APR 1 2 2012

To: Barbara Boockholdt
   Chief
   Regulatory Section
   Office of Diversion Control

From: Christine A. Sannerud, Ph.D.
   Chief
   UN Reporting and Quota Section
   Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject: 2012 Procurement Quota Increase Request

Oxycodone

(DFN: 630-08.2)

Date: APR 18 2012

To: Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From: Barbara J. Boockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On April 12, 2012, this section received your memorandum requesting a review of a quota increase submitted by(b)(4). ODQ is requesting a review of(b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately forty-five (45) of(b)(4) customers as well as on(b)(4).

The following information was found on(b)(4) and the below listed customers:

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Because two of(b)(4) customers are currently under review/investigation, ODG recommends that ODQ adjust the quota allotted to(b)(4) accordingly.

If you have any questions pertaining to this information, please feel free to contact me(b)(6);(b)(7)(C) or SC(b)(6);(b)(7)(C)
Addressed To: ODEQ
Location: ODEQ
Due: 05/11/2012
Received: 5/1/2012
Date Sent: 
Response: 
Security: A-AES
Abstract: Freedom Pharmaceuticals Inc 2012 procurement quota request oxycodone
Signature: C. Sannerud
Doc Categories: [b](6);[b](7)(C)
Doc Types: [b](6);[b](7)(C)
Memorandum

Subject

Freedom Pharmaceuticals, Inc.
2012 Procurement Quota Increase Request
Oxycodone (DFN: 630-08.2)

Date

MAY 1 2012

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From
Christine A. Sannerud, Ph.D.
Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant’s customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant’s enclosed customer list. Specifically, ODQ requests information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant’s quota allocation for oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject: Freedom Pharmaceuticals  (Fig 1)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DPN:630-08.2)

Date: MAY 01 2012

To: Christine A. Sammarud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From: Barbara J. Boeckholdt, Chief
Regulatory Section
Office of Diversion Control

On May 1, 2012, this section received your memorandum requesting a review of Freedom Pharmaceuticals’ customers list, specifically, information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Freedom Pharmaceuticals provided a list of (Fig 4) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Freedom Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me or SC

Vol. II Page 459
SBF-CM
Folder Details

Folder ID: 121262  
Reg No: [b](7)(E)

Author: [b](6);[b](7)(C)  
ODEQ

Addressed To: ODEQ

Location: ODEQ
Due: 05/13/2012
Received: 5/3/2012
Date Sent: 5/14/2012
Response: 

Security: A-AES
Abstract: [b](4) 2012 procurement quota request for hydrocodone

Signature: J. Rannazzisi

Doc Categories: [b](6);[b](7)(C)

Doc Types:

Action: Recommendation and Comments
Requested Activity:
Response Notes:

4/28/2015 10:44:06 AM
Memorandum

Subject
2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date
MAY 3 2012

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From
Christine A. Samuel, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:
As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant’s customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant’s enclosed customer list. Specifically, ODQ requests information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant’s quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject: 2012 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)

Date: MAY 1 1 2012

To

Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From
Barbara J. Bockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On May 3, 2012, this section received your memorandum requesting a review of a quota increase submitted by [(b)(4)] ODQ is requesting a review of [(b)(4)] customer list, specifically, information on whether the applicant’s customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred and six (106) of [(b)(4)] customers as well as an in-depth investigation of [(b)(4)].

The below listed information was found on customers:

Currently Under Review/Investigation

Currently Under Review/Investigation

Currently Under Review/Investigation

Based upon a review of [(b)(4)] customers, ODG recommends that ODQ adjust the quota granted to this company by at least the total kilogram amounts sold to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me or SC.
SBF-CM

Folder Details

Folder ID: 121261

Reg No: (b)(7)(E)

Author: (b)(6);(b)(7)(C)

ODEQ

Addressed To:

Location: ODEQ

Due: 05/13/2012

Received: 5/3/2012

Date Sent: 5/8/2012

Security: A-AES

Abstract: Aidarex 2012 procurement quota increase request for oxycodone

Signature: (b)(6);(b)(7)(C)

Doc Categories: (b)(6);(b)(7)(C)

Doc Types: ODG 05/10/2012 5/7/2012

Action: Recommendation and Comments

Requested Activity:

Response Notes:
Memorandum

Subject
Aiderex (D4X7E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date
MAY 3 2012

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From
Christine A. CarpenterPh.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:
As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant’s customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant’s enclosed customer list. Specifically, ODQ requests information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant’s quota allocation for hydrocodone.

ODQ notes from the attached documents that this registrant has procured oxycodone finished dosage forms in 2011 and 2012 without a quota.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject

Aidarex [b](4); [b](7)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date

MAY 07 2012

To

Christine A. Sannerud, Ph.D, Chief
UN Reporting and Quota Section
Office of Diversion Control

From

Barbara V. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 3, 2012, this section received your memorandum requesting a review of Aidarex's customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Aidarex provided a list of [b](4) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Freedom Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me [b](6); [b](7)(C) or SC [b](6); [b](7)(C)
**SBF-CM**

**Folder Details**

<table>
<thead>
<tr>
<th>Field</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Folder ID:</td>
<td>121263</td>
</tr>
<tr>
<td>Reg No:</td>
<td><em>(b)(7)(E)</em></td>
</tr>
<tr>
<td>Author:</td>
<td><em>(b)(6);(b)(7)(C)</em></td>
</tr>
<tr>
<td>Addressed To:</td>
<td>ODEQ</td>
</tr>
<tr>
<td>Location:</td>
<td>ODEQ</td>
</tr>
<tr>
<td>Due:</td>
<td>05/13/2012</td>
</tr>
<tr>
<td>Received:</td>
<td>5/3/2012</td>
</tr>
<tr>
<td>Data Sent:</td>
<td>5/8/2012</td>
</tr>
<tr>
<td>Security:</td>
<td>A-AES</td>
</tr>
<tr>
<td>Abstract:</td>
<td><em>(b)(4)</em> 2012 procurement quota increase request for oxycodone</td>
</tr>
<tr>
<td>Signature:</td>
<td><em>(b)(6);(b)(7)(C)</em></td>
</tr>
<tr>
<td>Doc Categories:</td>
<td><em>(b)(6);(b)(7)(C)</em></td>
</tr>
<tr>
<td>Doc Types:</td>
<td><em>(b)(4)</em></td>
</tr>
</tbody>
</table>

**Action:** Recommendation and Comments

**Requested Activity:**

**Response Notes:**

5/12/2015 1:56:46 PM

Vol. II Page 466
Memorandum

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From
Christine A. Sanner, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Subject
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date
MAY 3 2012

Background:
As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant’s customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant’s enclosed customer list. Specifically, ODQ requests information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant’s quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject: 2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date: MAY 07 2012

To: Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From: Barbara J. Boockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On May 3, 2012, this section received your memorandum requesting a review of a quota increase submitted by ODQ. ODG is requesting a review of the customer list, specifically, information on whether the applicant’s customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately twenty-three (23) of the customers as well as one (1) customer. The following information was found on one of the customers:

Currently Under Review/Investigation
(b)(4);(b)(7)(E)

Because one of the customers is currently under review/investigation, ODG recommends that ODQ adjust the quota allotted accordingly.

If you have any questions pertaining to this information, please feel free to contact me or SC.
SBF-CM

Folder Details

Folder ID: 121412

Reg No: [b](7)(E)

Author: [b](6);[b](7)(C)

ODEQ

Addressed To: ODEQ

Location: ODEQ

Due: 05/20/2012

Received: 5/10/2012

Date Sent: 5/14/2012

Response: A-AES

Abstract: Sun Pharmaceutical Industries 2012 procurement quota increase request for hydrocodone / oxycodone

Signature: Christine Sannerud

Doc Categories: [b](6);[b](7)(C)

Doc Types: ODG

05/17/2012 5/14/2012

Action: Recommendation and Comments

Requested Activity:

Response Notes:

5/12/2015 11:47:34 AM
Memorandum

Subject: Sun Pharmaceutical Industries, Inc. 2012 Procurement Quota Increase Request Hydrocodone / Oxycodone (DFN: 630-08.2)

To: Barbara Boockholdt
    Chief
    Regulatory Section
    Office of Diversion Control

From: Christine A. Samnerud, Ph.D.
    Chief
    Drug & Chemical Evaluation Section
    Office of Diversion Control

Date: MAY 10 2012

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone and oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant’s customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant’s enclosed customer list. Specifically, ODQ requests information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant’s quota allocation for hydrocodone and oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

To

Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Boocbholdt, Chief
Regulatory Section
Office of Diversion Control

On May 10, 2012, this section received your memorandum requesting a review of Sun Pharmaceuticals' customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Sun Pharmaceuticals provided a list of [redacted] customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. The check yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Sun Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me or SC.
<table>
<thead>
<tr>
<th>Folder ID: 521088</th>
<th>Reg No.: (b)(7)(E)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author:</strong> (b)(6);(b)(7)(C)</td>
<td><strong>Addressed To:</strong> ODEQ</td>
</tr>
<tr>
<td><strong>Location:</strong> ODEQ</td>
<td><strong>Due:</strong> 06/03/2012</td>
</tr>
<tr>
<td><strong>Received:</strong> 5/24/2012</td>
<td><strong>Date Sent:</strong></td>
</tr>
<tr>
<td><strong>Security:</strong> A-AES</td>
<td><strong>Response:</strong></td>
</tr>
<tr>
<td><strong>Abstract:</strong> Sovereign 2012 procurement quota increase request for hydrocodone</td>
<td><strong>Signature:</strong> J. Rannazzisi</td>
</tr>
<tr>
<td><strong>Doc Categories:</strong></td>
<td><strong>Doc Types:</strong></td>
</tr>
<tr>
<td>(b)(6);(b)(7)(C)</td>
<td>ODG 05/31/2012 5/29/2012</td>
</tr>
<tr>
<td><strong>Action:</strong> Recommendation and Comments</td>
<td></td>
</tr>
<tr>
<td><strong>Requested Activity:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Response Notes:</strong></td>
<td></td>
</tr>
</tbody>
</table>
Memorandum

Subject: 2012 Procurement Quota Increase Request
Hydrocodone (DFN: 630-08.2)

Date: MAY 24 2012

To: Barbara Boockholdt
   Chief
   Regulatory Section
   Office of Diversion Control

From: Christine A. Sannerud, Ph.D.
      Chief
      UN Reporting and Quota Section
      Office of Diversion Control

Background:
As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2012 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.
SBF-CM

Folder Details

Folder ID: 121635
Reg No: (b)(7)(E)
Reg No: (b)(6);(b)(7)(C)

Addressed To:

Location: ODEQ
Author: ODEQ
Due: 06/03/2012
Received: 5/24/2012
Date Sent: Response:

Security: A-AES
Abstract: Metrics Inc 2012 procurement quota increase request for oxycodone
Signature: Charstine Sannerud
Doc Categories: Doc Types:

Action: ODG 05/31/2012 5/29/2012
Requested Activity: Recommendation and Comments
Response Notes:
Memorandum

Subject
Metrics, Inc.
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date
MAY 24 2012

To
Barbara Boockholdt
Chief
Regulatory Section
Office of Diversion Control

From
Christine A. Sannerud, Ph.D.
Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

Background:
As a result of the recent increase in the diversion and abuse of oxycodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2011 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for oxycodone.

Please feel free to contact me if I can provide further assistance in this matter.
Memorandum

Subject
Metrics, Inc. [b](4);[b](7)(E)
2012 Procurement Quota Request
Oxycodone
(DFN:630-08.2)

Date
MAY 25 2012

To
Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Bockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 24, 2012, this section received your memorandum requesting a review of Metrics, Inc.'s customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Metrics, Inc. provided a list of customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. This check yielded the following result:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Metrics, Inc. for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me or SC

Vol. II Page 476
Memorandum

To
Christine A. Sanncrud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Bockholdt, Chief
Regulatory Section
Office of Diversion Control

On June 5, 2012, this section received your memorandum requesting a review of [b](4) customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

[b](4) provided a list of ten (10) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

Retired 6/1/12

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by [b](4) for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me [b](6), [b](7) or SC [b](6), [b](7).
Memorandum

Subject
(b)(4) 2012 Procurement Quota Increase Request Oxycodone (DFN: 630-08.2)

Date
JUN 14 2012

To
Christine A. Sannerud, Ph.D., Chief Drug & Chemical Evaluation Section (ODQ) Office of Diversion Control

From
Barbara J. Boockholdt, Chief Regulatory Section (ODG) Office of Diversion Control

On June 7, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4) ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant’s customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-five (95) of (b)(4) customers as well as an in-depth investigation of (b)(4). The below listed information was found on (b)(4) customers:

<table>
<thead>
<tr>
<th>Currently Under Review/Investigation</th>
</tr>
</thead>
<tbody>
<tr>
<td>(b)(4);(b)(7)(E)</td>
</tr>
<tr>
<td>(b)(4);(b)(7)(E)</td>
</tr>
<tr>
<td>(b)(4);(b)(7)(E)</td>
</tr>
</tbody>
</table>

Vol. II Page 478
Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Nine (9) of (b)(4) customers are under Review/Investigation and one (1) is retired.

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me or SC.
Memorandum

Subject
Sovereign (b)(4); (b)(7)(E)
2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date
JUN 27 2012

To
Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Bockholdt, Chief
Regulatory Section
Office of Diversion Control

On June 27, 2012, this section received your memorandum requesting a review of Sovereign's customers list, specifically, information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Sovereign provided a list of (b)(4) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. The DEA registration number was also run through RICS to determine if the registration was current. This check yielded the following result:

No derogatory information was found.

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Sovereign for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me. [Redacted] or SC [Redacted].

Vol. II Page 480
Memorandum

Subject
Roadrunner Pharmacy (b)(4); (b)(7); (E)
2012 Procurement Quota
Hydrocodone
(DFN: 630-08.2)

To
Christine A. Sannerud, Ph.D., Chief
UN Reporting & Quota Section (ODQ)
Office of Diversion Control

From
Barbara J. Brackholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

Date
JUL 19 2012

On July 17, 2012, this section received your memorandum requesting a review of a quota increase submitted by Roadrunner Pharmacy. ODQ is requesting a review of Roadrunner Pharmacy’s customer list, specifically, information on whether the applicant’s customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately (b)(4) of Roadrunner’s customers as well as an in-depth investigation of Roadrunner Pharmacy.

The below listed information was found on Roadrunner’s customers:

NO DEROGATORY INFORMATION WAS FOUND

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Roadrunner Pharmacy for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me or SC.
Memorandum

Subject
2012 Procurement Quota Increase Request
Oxycodone
(DFN:630-08.2)

Date
AUG 01 2012

To
Christine A. Sannerud, Ph.D, Chief
UN Reporting & Quota Section
Office of Diversion Control

From
Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On July 17, 2012, this section received your memorandum requesting a review of customers list, specifically, information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

provided a list of five (05) customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

Currently Under/Review Investigation
Currently Under/Review Investigation

DEA does not have sufficient grounds to limit, restrict, or deny a quota request from this registrant.

If you have any questions pertaining to this information, please feel free to contact me or SC.
Memorandum

To
Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Bockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On August 2, 2012, this section received your memorandum requesting a review of a quota increase submitted by [(b)(4)] ODQ is requesting a review of [(b)(4)] customer list, specifically, information on whether the applicant’s customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately sixty one (61) of [(b)(4)] customers as well as an in-depth investigation of [(b)(4)]

The below listed information was found on [(b)(4)] customers:

- Currently Under Review/Investigation
  [(b)(4);(b)(7)(E)]

- Currently Under Review/Investigation
  [(b)(4);(b)(7)(E)]

- Currently Under Review/Investigation
  [(b)(4);(b)(7)(E)]

- Currently Under Review/Investigation
  [(b)(4);(b)(7)(E)]
Based upon a review of [redacted] customers, ODG recommends that ODQ adjust the quota granted to this company by at least the total kilogram amounts sold to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me [redacted] or PA [redacted].
Memorandum

Subject
2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date
SEP 10 2012

To
Christine A. Sannerud, Ph.D., Chief
UN Reporting and Quota Section (ODQ)
Office of Diversion Control

From
Barbara J. Boochoeldt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On August 29, 2012, this section received your memorandum requesting a review of a quota increase submitted by ODQ is requesting a review of customer list, specifically, information on whether the applicant’s customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-seven (97) of customers as well as an in-depth investigation of customers:

- Order to Show Cause Requested to CC
- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Review/Investigation

The below listed information was found on customers:

- (b)(4)
- (b)(4)
- (b)(4)
Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Ten (10) of (b)(4) customers are under Review/Investigation.

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me or SC.
On September 11, 2012, this section received your memorandum requesting a review of Mikart Inc.'s customers list, specifically, information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

Mikart Inc. provided a list of customers. The names of the customers were run through NADDIS to determine if there were any open field investigations. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

No derogatory information was found

DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the request submitted by Freedom Pharmaceuticals for the quota increase.

If you have any questions pertaining to this information, please feel free to contact me or SC.
Memorandum

Subject
(b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request Hydrocodone (DFN:630-08.2)

Date
SEP 17 2012

To
Christine A. Sannerud, Ph.D, Chief
UN Reporting and Quota Section
Office of Diversion Control

From
Barbara J. Bodeckholdt, Chief
Regulatory Section
Office of Diversion Control

On September 10, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of (b)(4) customers list, specifically, information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred fifty-nine (159) of (b)(4) customers as well as on (b)(4)

The below listed information was found on (b)(4) customers:

(b)(4);(b)(7)(E) Retired in 7/2012
(b)(4);(b)(7)(E) Retired 7/05/2012
(b)(4);(b)(7)(E) Currently Under Review/Investigation
(b)(4);(b)(7)(E) Currently Under Review/Investigation

Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Two of (b)(4) customers are currently retired and three (3) customers are under review/investigation.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C).
Memorandum

Subject: 2012 Procurement Quota Increase Request
         Oxycodone
         (DFN: 630-08.2)

Date: SEP 17 2012

To:
Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section (ODQ)
Office of Diversion Control

From:
Barbara J. Bockholdt, Chief
Regulatory Section (ODG)
Office of Diversion Control

On August 31, 2012, this section received your memorandum requesting a review of a quota increase submitted by ODQ is requesting a review of customer list, specifically, information on whether the applicant’s customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately ninety-six (96) customer list, specifically, as well as an in-depth investigation of customers:

The below listed information was found on customer list:

- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Review/Investigation
Based upon a review of customers, ODG recommends that ODQ adjust the quota granted to this company. Ten (10) of customers are under Review/Investigation and one (1) is retired.

Quota to should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me or PA.
On September 18, 2012, this section received your memorandum requesting a review of a quota increase submitted by ODQ is requesting a review of customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred and seventy two (172) of customers as well as an in-depth investigation of

The below listed information was found on customers:

- Currently Under Review/Investigation
- Currently Under Review/Investigation
- Currently Under Suspension
- Currently Under Under/Review
- Currently Under Under/Review
Based upon a review of customers, ODG recommends that ODG adjust the quota granted to this company. Sixteen (16) of customers are under Currently Under Review/Investigation, Two (2) are Currently Under Suspension, and one (1) is Retired Quota should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me or PA.
Memorandum

Subject
(b)(4);(b)(7)(E)
2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date

To
Christine A. Sannerud, Ph.D.,
Chief
UN Reporting and Quota Section
Office of Diversion Control

From
Barbara J. Boocckholdt,
Chief
Regulatory Section
Office of Diversion Control

On September 27, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of the applicant's customers, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred and nine (109) of the customer list, specifically,

The below listed information was found on customers:

Currently Under Review/Investigation

Currently Under Review/Investigation

Order to Show Cause Requested

Currently Under Review/Investigation

Currently Under Review/Investigation

Currently Under Review/Investigation
Based upon a review of customers, ODG recommends that ODQ adjust the quota granted to this company. Nine (9) of customers are under Review/Investigation, one (1) has been issued an Order to Show Cause (OTSC), one (1) is Under Suspension and one (1) is Retired.

Quota to should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me or PA.
Memorandum

Subject: 2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date: NOV 09 2012

To: Christine A. Sannerud, Ph.D.,
Chief
UN Reporting and Quota Section
Office of Diversion Control

From: Barbara A. Bodekholdt,
Chief
Regulatory Section
Office of Diversion Control

On October 8, 2012, this section received your memorandum requesting a review of a quota increase submitted by the [b](4) ODQ is requesting a review of the (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately one hundred forty-four (144) of the (b)(4) customers as well as an in-depth investigation of the (b)(4) customers:

The below listed information was found on the (b)(4) customers:

- Currently Under Review/Investigation
  - (b)(4);(b)(7)(E)

- Currently Under Review/Investigation
  - (b)(4);(b)(7)(E)

- Currently Under Review/Investigation
  - (b)(4);(b)(7)(E)

- Currently Under Review/Investigation
  - (b)(4);(b)(7)(E)

- Currently Under Review/Investigation
  - (b)(4);(b)(7)(E)
Based upon a review of (b)(4) customers, ODG recommends that ODQ adjust the quota granted to this company. Nine (9) of (b)(4) customers are under Review/Investigation, (b)(4);(b)(5);(b)(7)(E)

Quota to (b)(4) should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or PA (b)(6);(b)(7)(C)

Cc: Christine ASannerud, Ph.D /Chief/ODQ/UN Reporting and Quota Section

Cc: ODG

Cc: ODGR 11/9/2012: Req Doc: 10/18/2012
Memorandum

Subject: 2012 Procurement Quota Increase Request
Oxycodone
(DFN: 630-08.2)

Date: NOV 29 2012

To:
Christine A. Sannerud, Ph.D.,
Chief
UN Reporting and Quota Section
Office of Diversion Control

From:
Barbara J. Boeckholdt,
Chief
Regulatory Section
Office of Diversion Control

On November 13, 2012, this section received your memorandum requesting a review of a quota increase submitted by (b)(4). ODQ is requesting a review of (b)(4) customer list, specifically, information on whether the applicant's customers are currently under investigation or are subject of an order to show cause or immediate suspension order.

ODGR conducted NADDIS and CSA reviews of approximately fifty-nine (59) of (b)(4) customers as well as an in-depth investigation of (b)(4) customers:

- Currently Under Review/Investigation
  (b)(4);(b)(7)(E)

- Currently Under Review/Investigation
  (b)(4);(b)(5);(b)(7)(E)

- Currently Under Review/Investigation
  (b)(4);(b)(7)(E)

- Currently Under Suspension
  (b)(4);(b)(7)(E)
Based upon a review of [redacted] customers, ODG recommends that ODQ adjust the quota granted to this company. Three (3) of [redacted] customers are under Review/Investigation, one (1) is currently Under Suspension.

Quota to [redacted] should be reduced by at least the total kilogram amounts sold by the company to the above listed customers.

If you have any questions pertaining to this information, please feel free to contact me [redacted] or PA [redacted].
Memorandum

Subject: 2012 Procurement Quota Increase Request
Hydrocodone
(DFN: 630-08.2)

Date: NOV 29 2012

To
Christine A. Sannerud, Ph.D, Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From
Barbara J. Boogholdt, Chief
Regulatory Section/ODG
Office of Diversion Control

On November 28, 2012, this section received your memorandum requesting a review of the customer list, specifically, information on whether the applicant’s customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. You provided a list of one (1) customer. The name of the customer was run through NADDIS to determine if there were any open field investigations. ODGR has checked with the DEA on this matter. The DEA registration numbers were also run through RICS to determine if the registrations were current. These checks yielded the following results:

At this time it does not appear that DEA has sufficient legal grounds to limit, restrict, or deny quota requests from this registrant. Based on this information, ODG suggests that you proceed with the completion of the request submitted by [redacted] or an increase of their quota.

If you have any questions pertaining to this information, please feel free to contact me or PA [redacted].